Vera Therapeutics, Inc. (NASDAQ: VERA) has received U.S. FDA Accelerated Approval for TRUTAKNA™ (atacicept-vymj) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. Sector: Biotechnology Key Highlights: 🏥 FDA Accelerated Approval for TRUTAKNA™ (atacicept-vymj) 🧬 First and only therapy targeting both BAFF and APRIL pathways 📊 Phase 3 ORIGIN trial showed a 46% reduction in proteinuria from baseline and 42% vs. placebo (p<0.0001) at 36 weeks 💉 Convenient once-weekly subcutaneous self-injection via autoinjector 🎯 Targets the underlying immunological cause of IgA nephropathy (IgAN) TRUTAKNA offers a new targeted treatment option for IgAN, a progressive kidney disease that can lead to kidney failure. The approval was based on proteinuria reduction; continued approval may require confirmatory data on kidney function preservation. https://www.thinksabio.com/reports/isr/VERA